Switch theme
Sign up to access all valuation multiples
CROSSJECT manufactures and markets needle-free drug self-injection system.
2002
54
LTM Revenue $20.8M
LTM EBITDA -$2.2M
$53.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CROSSJECT has a last 12-month revenue of $20.8M and a last 12-month EBITDA of -$2.2M.
In the most recent fiscal year, CROSSJECT achieved revenue of n/a and an EBITDA of -$8.3M.
CROSSJECT expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CROSSJECT valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | n/a | XXX | XXX | XXX |
| Gross Profit | -$1.3M | -$6.6M | XXX | XXX | XXX |
| Gross Margin | -832% | -Infinity% | XXX | XXX | XXX |
| EBITDA | -$7.8M | -$8.3M | XXX | XXX | XXX |
| EBITDA Margin | -5032% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$12.0M | -$9.3M | XXX | XXX | XXX |
| Net Margin | -7694% | -Infinity% | XXX | XXX | XXX |
| Net Debt | $6.8M | $17.8M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, CROSSJECT's stock price is EUR 1 (or $1).
CROSSJECT has current market cap of EUR 38.7M (or $41.5M), and EV of EUR 50.0M (or $53.7M).
See CROSSJECT trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53.7M | $41.5M | XXX | XXX | XXX | XXX | $-0.14 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, CROSSJECT has market cap of $41.5M and EV of $53.7M.
CROSSJECT's trades at 2.6x LTM EV/Revenue multiple, and -24.9x LTM EBITDA.
Analysts estimate CROSSJECT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CROSSJECT and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $53.7M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -6.5x | XXX | XXX | XXX |
| P/E | -3.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCROSSJECT's NTM/LTM revenue growth is 96%
CROSSJECT's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.1M for the same period.
Over next 12 months, CROSSJECT's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CROSSJECT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CROSSJECT and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -100% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 6% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CROSSJECT acquired XXX companies to date.
Last acquisition by CROSSJECT was XXXXXXXX, XXXXX XXXXX XXXXXX . CROSSJECT acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CROSSJECT founded? | CROSSJECT was founded in 2002. |
| Where is CROSSJECT headquartered? | CROSSJECT is headquartered in France. |
| How many employees does CROSSJECT have? | As of today, CROSSJECT has 54 employees. |
| Is CROSSJECT publicy listed? | Yes, CROSSJECT is a public company listed on PAR. |
| What is the stock symbol of CROSSJECT? | CROSSJECT trades under ALCJ ticker. |
| When did CROSSJECT go public? | CROSSJECT went public in 2014. |
| Who are competitors of CROSSJECT? | Similar companies to CROSSJECT include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of CROSSJECT? | CROSSJECT's current market cap is $41.5M |
| What is the current revenue of CROSSJECT? | CROSSJECT's last 12-month revenue is $20.8M. |
| What is the current EBITDA of CROSSJECT? | CROSSJECT's last 12-month EBITDA is -$2.2M. |
| What is the current EV/Revenue multiple of CROSSJECT? | Current revenue multiple of CROSSJECT is 2.6x. |
| What is the current EV/EBITDA multiple of CROSSJECT? | Current EBITDA multiple of CROSSJECT is -24.9x. |
| Is CROSSJECT profitable? | Yes, CROSSJECT is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
